Jubilant Pharmova Ltd (Jubilant) is an integrated pharmaceutical company. The company manufactures and supplies active pharmaceutical ingredients (APIs), solid dosage formulations, allergy therapy products, and radiopharmaceuticals. Jubilant Pharmova Limited was initially incorporated as 'Vam Organic Chemicals Limited' on June 21, 1978. The Company name was thereafter changed to 'Jubliant Organosys Limited' in November 2001 and to 'Jubilant Life Sciences Limited' in October 2009, and the Company attained its new name 'Jubilant Pharmova Limited' in February 2021.
Jubilant is headquartered in Noida, Uttar Pradesh, India. Jubilant Pharmova has 5,750 total employees. As part of the Jubilant Bhartia Group, the company has evolved into a specialized pharmaceutical entity with global operations spanning across multiple therapeutic areas and advanced manufacturing capabilities.
The company operates in the following segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs.
In the Radiopharma business, the Company is involved in manufacturing and supply of Radiopharmaceuticals with a network of 46 radio-pharmacies in the US. The company is the #3 radiopharmaceutical manufacturer in the US and has the #2 network in the US with 46 radiopharmacies. This segment represents approximately 44% of the company's revenue contribution as of 9M FY24. In 9M FY24, sale of Mertiatide, Sulfur colloid) and Ruby-Fill did very well. RUBY-FILL is a cardiac imaging product.
The Company's Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in US, Canada, Europe and Australia. Offering a range of over 200 different allergenic extracts and standard allergy vaccine. This division focuses on specialized diagnostic devices for skin testing and venom immunotherapy products.
Jubilant through its CDMO Sterile Injectables, business offers manufacturing services including sterile fill and finish injectables (both liquid and lyophilization), full-service ophthalmic offer (liquids, ointments & creams) and ampoules. Jubilant offers contract manufacturing services for sterile injectables and non-sterile products and drug discovery services.
With more than 20 years of experience in drug discovery, Jubilant Biosys stands at the forefront of the pharmaceutical and health science sectors, offering a comprehensive suite of services encompassing drug discovery, contract research, development, and manufacturing. Our dedicated team comprises over 1,120 highly talented scientists, with operations in India and a presence in Europe, the USA, and Japan, all motivated by a science and solution-oriented mind-set.
Jubilant Pharmova has a Market Cap of ₹19,020 Crore. The Jubilant Pharmova Ltd's 52-week high share price is ₹1,309.00 and 52-week low share price is ₹701.40. The company's market capitalization has shown significant growth, with the stock price appreciating substantially over the past few years.
For the full year, net profit rose 988.72% to ₹839.40 Crore in the year ended March 2025, as against ₹77.10 Crore during the previous year ended March 2024. Sales rose 8.24% to ₹7,192.10 Crore in the year ended March 2025, as against ₹6,644.80 Crore during the previous year ended March 2024.
Key Financial Highlights for FY25:
- Revenue: ₹1,915.80 Crore as on March 2025 (Q4 FY25). Net Profit: ₹151.30 Crore as on March 2025 (Q4 FY25).
- The profit after tax also rebounded significantly to ₹836.80 Crore in March 2025, compared to a loss of ₹77.13 Crore in March 2023. The earnings per share (EPS) reflected this recovery, rising to ₹53.13 in March 2025 from a negative EPS of ₹-3.83 in March 2023.
Company has reduced debt. Company's working capital requirements have reduced from 59.9 days to 30.2 days. These improvements demonstrate the company's focus on operational efficiency and financial discipline.
Jubilant Pharmova Ltd has declared a 500% dividend - ₹5 per share. Jubilant Pharmova Ltd. has an upcoming dividend of ₹5.00 per share due on July 25, 2025. Promoter holding in Jubilant Pharmova Ltd has remained stable at 50.68% as of March 2025 (unchanged from June 2024).
It owns and operates cGMP-compliant manufacturing facilities, and research and development centers in India, the US, and Canada. The company provides its products and services to customers across the US, India, South Africa, Canada, Singapore, Belgium, and China.
The company maintains a robust global presence with manufacturing facilities and research centers strategically located across multiple continents. This geographic diversification allows Jubilant Pharmova to serve customers in regulated markets while maintaining high-quality standards and compliance with international regulatory requirements.
The Composite Scheme of Arrangement for amalgamation of certain promoter controlled entities into the Company and demerger of the Life Science Ingredients business into Jubilant Ingrevia Limited, the Resulting entity, was approved by Honble National Company Law Tribunal (NCLT), Allahabad Bench vide its Order dated December 23, 2020. The said NCLT Order was filed with the Registrar of Companies by the Company and the Resulting entity on February 1, 2021, thereby making the Composite Scheme effective. Effective February 1, 2021, the Life Science Ingredients business demerged from Jubilant Pharmova Limited.
Jubilant Pharmova's board approved the sale and transfer of its active pharmaceutical ingredients (API) business on a slump sale basis to Jubilant Biosys, a wholly-owned subsidiary. The API business of the company achieved turnover of ₹609 Crore, representing 8.35% of the consolidated turnover for the financial year ended March 31, 2025.
Jubilant Pharmova has an operating revenue of ₹7,234.50 Crore on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 14% is healthy, ROE of 13% is good. The company has a reasonable debt to equity of 34%, which signals a healthy balance sheet.
The P/B ratio of Jubilant Pharmova Ltd is 2.87 times as on June 19, 2025, a 21% discount to its peers' median range of 3.63 times. The P/E ratio of Jubilant Pharmova Ltd is 21.38 times as on June 19, 2025, a 44% discount to its peers' median range of 38.24 times.
Jubilant Pharmova Limited stands as a well-established pharmaceutical company with a diversified portfolio spanning radiopharmaceuticals, allergy therapy, contract manufacturing, and novel drug development. The company's strong financial recovery, operational improvements, and strategic focus on high-growth segments position it favorably in the competitive pharmaceutical landscape. With its global manufacturing footprint, strong research capabilities, and leadership positions in key therapeutic areas, Jubilant Pharmova continues to build value for stakeholders while maintaining its commitment to delivering innovative healthcare solutions.
